Sana is a pure pipeline story, the Q1 results are directionally neutral as losses narrowed slightly and cash runway extended. The key catalysts are IND filings and Phase 1 starts for SC451 and SG293 later this year. Watch for ASGCT presentation on May 12 for SG293 preclinical data. The Mayo collaboration provides validation but the stock will move on clinical data, not financials.
Price Chart
Executive Summary
Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than the $0.21 loss in Q1 2025, but the company remains a pre-revenue biotech with no approved products. Cash burn continues at ~$37M/quarter, and the cash runway was extended into 2027 via a $25M equity investment from Mayo Clinic as part of a strategic collaboration. The stock will trade on pipeline catalysts, IND filings for SC451 and SG293 expected later this year, rather than financial results.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP net loss of $47.2M ($0.17/share) vs $49.4M ($0.21/share) in Q1 2025
- Cash position of $101.1M at March 31, 2026, down from $138.4M at December 31, 2025
- Pro forma cash of $128.9M including $25M equity investment from Mayo Clinic collaboration
- Non-GAAP operating cash burn of $37.0M in Q1 2026 vs $46.6M in Q1 2025
- Mayo Clinic made a $25M equity investment with option for an additional $25M
- Expects to file IND and begin Phase 1 trial for SC451 (type 1 diabetes) later this year
- Expects to begin clinical study for SG293 (non-Hodgkin lymphoma) later this year
- SG227 (BCMA-targeted CAR T) expected to begin clinical testing as early as mid-2027
- UP421 study showed ongoing islet cell survival and function at 14 months post-transplant
- No revenue, pre-recovery biotech with no approved products
Financial Impact
Q1 2026 net loss of $47.2M, cash burn of $37.0M, cash runway extended into 2027 via $25M equity investment
Risk Factors
- Pre-revenue biotech with no approved products, entirely dependent on clinical trial success
- Cash runway only into 2027, likely to need additional financing before data readouts
- Clinical trial delays or negative data could severely impact stock price
- Dilution risk from ongoing ATM and potential future equity offerings
- Contingent consideration liabilities of $151.4M could materially impact balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-216758 |
| Document: sana-20260511.htm | 0001193125-26-216758 |
| Document: 0001193125-26-216758-index-headers.html | 0001193125-26-216758 |
| Document: 0001193125-26-216758-index.html | 0001193125-26-216758 |
| Document: 0001193125-26-216758.txt | 0001193125-26-216758 |
| 8-K Data (Synthetic) | 0001193125-26-216758 |
Track record
12 reports on SANA
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 Viewing No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers